[Uricemia-lowering activity of losartan in kidney transplantation].
Otero Glz
A
A
Pérez Melón
C
C
Armada
E
E
Gayoso
P
P
D000328:Adult; D016572:Cyclosporine / Q000009:adverse effects / Q000494:pharmacology; D004341:Drug Evaluation; D015672:Erythroid Precursor Cells / Q000187:drug effects; D004921:Erythropoietin / Q000378:metabolism; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000494:pharmacology; D016030:Kidney Transplantation; D007684:Kidney Tubules / Q000187:drug effects / Q000503:physiopathology; D019808:Losartan / Q000494:pharmacology* / Q000627:therapeutic use; D008875:Middle Aged; D011086:Polycythemia / Q000209:etiology; D011183:Postoperative Complications / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy*; D044140:Receptor, Angiotensin, Type 1; D011945:Receptors, Angiotensin / Q000187:drug effects* / Q000502:physiology; D012079:Renal Circulation / Q000187:drug effects; D016896:Treatment Outcome; D014527:Uric Acid / Q000097:blood*
D007166:Immunosuppressive Agents; D044140:Receptor, Angiotensin, Type 1; D011945:Receptors, Angiotensin; D004921:Erythropoietin; D014527:Uric Acid; D016572:Cyclosporine; D019808:Losartan